Drug Trial Radar · NCT04338399
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
487
Actual
Start
Dec 12, 2020
Primary completion
Nov 2, 2025
Study completion Nov 2, 2025
Sponsor
- Lead sponsor
- Adlai Nortye Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.
Conditions
- Head and Neck Cancer
Interventions
Buparlisib & PaclitaxelDrug
Investigation drug plus paclitaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Overall survival will be measured from time of randomization until death from any cause. The analysis will occur when all patients have been randomized and followed for 12 months.
Locations
162 sites in 17 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Yale University, Yale Cancer Center
New Haven, Connecticut
Moffitt Cancer Center
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Kentucky
Lexington, Kentucky
Norton Cancer Institute
Louisville, Kentucky
University of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
NYU Langone
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
Montefiore Medical Center
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Cancer Center
Cincinnati, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Hollings Cancer Center
Charleston, South Carolina
West Cancer Center
Germantown, Tennessee
Hope Cancer Center, UT Health East Texas
Tyler, Texas
Fundacion Cenit para la Investigacion en Neurociencias
Buenos Aires, Argentina
Centro de Investigacion Pergamino SA - Clinica Pergamino S.A.
Buenos Aires, Argentina
Instituto de Investigaciones Metabólicas (IDIM) // Instituto de Investigaciones Metabólicas S.A.
Ciudad Autonoma de Buenos Aire, Argentina
IONC SRL- Instituto Oncológico de Córdoba
Córdoba, Argentina
Fundacion CORI para la Investigacion y Prevencion del Cáncer
La Rioja, Argentina
Centro para la Atencion Integral del Paciente Oncologico - CAIPO
San Miguel de Tucumán, Argentina
Princess Alexandra Hospital
Brisbane, Australia
Universitair Ziekenhuis Gent UZ Gent
Ghent, Belgium
Universitair Ziekenhuis Brussel
Jette, Belgium
Clinique CHC MontLégia
Liège, Belgium
Clinique Saint-Pierre dOttignies CSPO
Ottignies, Belgium
CHUM
Montreal, Canada
CancerCare Manitoba
Winnipeg, Canada
Beijing Tongren Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Hunan Cancer Hospital
Changsha, China
Xiangya Hospital Central South University
Changsha, China
Sichuan Cancer Hospital
Chengdu, China
Affiliated Cancer Hospital of Chongqing University
Chongqing, China
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.